Skip to content

Lifecore Biomedical, Inc. LFCR Long-term debt, gross

Long-term debt, gross at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
ADMA Biologics logo
ADMA BiologicsADMA
ClearPoint Neuro logo
ClearPoint NeuroCLPT
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s long-term debt, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s long-term debt, gross?
Lifecore Biomedical, Inc. (LFCR) reported long-term debt, gross of $200.06M in Q1 2026.
What is the long-term trend for Lifecore Biomedical, Inc.'s long-term debt, gross?
Over 2 years (2023 to 2026), Lifecore Biomedical, Inc.'s long-term debt, gross has grown at a 15.4% compound annual growth rate (CAGR), from $150.23M to $200.06M.